Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202976 | 0.86 | KMT2A (0.45) | KMT2ASMN1; SMN2ACHECHRM4TLR9 | |
| SCHEMBL17176550 | 0.83 | KMT2A (0.43) | KMT2ASMN1; SMN2ACHECHRM4TLR9 | |
| SCHEMBL7858206 | 0.81 | KDM4E (0.40) | KMT2ASMN1; SMN2KDM4EHSD11B1 | |
| SCHEMBL18608956 | 0.80 | KMT2A (0.41) | KMT2ASMN1; SMN2ACHE | |
| SCHEMBL18199687 | 0.80 | KMT2A (0.41) | KMT2ASMN1; SMN2ACHECHRM4HSD11B1 | |
| SCHEMBL11919058 | 0.79 | KMT2A (0.56) | KMT2ASMN1; SMN2ACHECHRM4KDM4E | |
| SCHEMBL11919045 | 0.79 | KMT2A (0.56) | KMT2ASMN1; SMN2ACHECHRM4HSD11B1 | |
| SCHEMBL27267682 | 0.78 | KMT2A (0.42) | KMT2ASMN1; SMN2ACHETLR9TLR7 | |
| SCHEMBL15806910 | 0.78 | ALDH1A1 (0.41) | KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL13548824 | 0.77 | KMT2A (0.50) | KMT2ASMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | KMT2A 2280/4885SMN1; SMN2 2262/4885ACHE 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.